A human Hanganutziu-Deicher (HD) antibody and a chicken anti-N-glycolylneuraminyllactosylceramide (HD3) antibody were compared in their reaction against HD antigen-active ganglioside (HD3) and a glycoprotein (GP) by radioimmunassay (RIA). The human antibody had a 50 times higher reactivity with the glycoprotein, while the chicken antibody reacted equally with both antigens. Both antibodies had a higher reactivities with HD antigen(s) in sera of five of eight lung cancer patients than 54 normal human sera. Since four of the above five sera had no abnormal titers to GP, it was concluded that their immunological status was antigen excess. The chicken antibody may be useful in follow-up studies of cancer patients to correlate the expression of HD antigen in tissues and sera with the elevation of HD antibodies, offering alternative methods of clinical prognosis of tumor growth and/or metastases.
INTRODUCTION
Heterophile Hanganutziu-Deicher (HD) antibodies were originally detected in the sera of patients who had received therapeutic injections of serum of a foreign species (1, 2) . Patients of various diseases who had never received injections of foreign serum were also found to possess HD type of heterophile antibodies (3) . Gangliosides with HD antigenic molecules were purified from equine and bovine erythrocytes and identified as N-glycolylneuraminyllactosylceramide (HD3) and N-glycolylneuraminyllactoneotetraosylceramide (HD5), respectively (Table I) .
Since both compounds show the same reaction with HD antibodies, the common disaccharide portion (N-glycolylneuraminic acid-galactose) of the two is believed to be the specific antigenic moiety (4, 5) . A major glycoprotein of bovine erythrocytes was also found to be highly antigenic (6) and the structure of an alkali-labile oligosaccharide (7) from the glycoprotein was found to possess a disaccharide group identical to that of HD3 and HD5 (Table I ).
The immunodominant group of HD antigens is N-glycolylneuraminic acid (Neu5Gc) and this type of sialic acid is distributed in many mammalian species, with the exception of humans and chickens (8-10). Human malignant tissues express HD antigens and this has been demonstrated by the hemagglutination test (11) and by indirect membrane immunofluorescence (12) . Limitations with the above methods are either sensitivity or the readings are subjective and difficult to interpret in borderline cases. An enzyme-immunostaining method was used for the detection of Neu5Gc-containing glycosphingolipids (13) . This technique, though being sensitive, has a drawback in that it can be used only on extracted or purified ganglioside samples.
To maximize the detection of an HD antigen which may be a ganglioside or a glycoprotein, an RIA procedure with a purified labeled glycoprotein as the antigen was developed (14) . Cancer patients are known to possess HD antibodies (15, 16) . Compared to normal human sera, those of cancer patients are reported to have higher levels of lipid-bound sialic acid (17, 18) . With this understanding, this study was undertaken to evaluate the use of the RIA system which is capable of detecting an HD antigen-active ganglioside or a glycoprotein in tissues and sera. We compared the use of human HD antibody (human system) with that of chicken anti-HD3 antibody (chicken system) in the detection of HD antigen(s) in normal and lung cancer patients.
The information obtained will be useful in the follow-up studies of cancer patients. Sera for detection of HD antigen(s) and antibody: Fifty-four normal human sera were obtained from apparently healthy blood donors at the Hokkaido Red Cross Blood Center. Eight sera from hospitalized lung cancer patients were obtained from Hokkaido University Hospital (thanks to Dr. M. Hashimoto, Second Department of Surgery, Faculty of Medicine). Chicken anti-HD3 serum was obtained by immunizing chickens with pure HD3 as reported (9) .
Sialoglyco-conjugates for test of HD antigenicity: Bovine erythrocyte major glycoprotein was prepared as previously described (6). The glycoprotein with a molecular weight of about 230,000 (19) consists of 80% carbohydrate and 20% protein by weight. The glycoprotein was found to possess a strong HD antigen potency (6). HD3 and HD5 were purified from horse and bovine erythrocytes, respectively (15 Production and dissociation of an artificial immune-complex: To 400 pl of buffer was added 50 pl of 20 pglml of cold glycoprotein and 50 pl of undiluted human HD antibody-containing serum (T.T.). The final dilution in the tube was 10 times for both the HD serum and glycoprotein. The mixture was left at 4 C for 72 hr, boiled at 100 C for 10 min and centrifuged at 10,000 rpm for 30 min. The resultant supernatant (50 pl, containing 100 ng of glycoprotein) and its 1:2 serial dilutions were used for the inhibition experiment. The control consisted of a mixture containing 50 pl of buffer instead of HD serum. 
RESULTS

Establishment of the RIA System
To obtain a suitable amount of HD antibody-containing serum for RIA, a typical HD antibody-containing serum from a patient with cancer and chicken anti-HD3 antibody-containing serum were titrated. The lowest dilution used
(1:100) bound 76% of 125I-GP in the human system and 85% in the chicken system (Fig. 1) . From these curves, 50 pl of a 1:400 dilution of human HD antibody- (Fig. 2) . From these inhibitor titrations, 3.9 ng of cold glycoprotein and 195 ng of HD3 were found to inhibit 50% binding of 1251-GP in the human system . On the other hand, 3.5 ng of cold glycoprotein and 6.6 ng of HD3 inhibited 50% binding in the chicken system (Fig. 2) . Cold glycoprotein was allowed to react with an excess amount of HD antibody (A) or without antibody (0) for 3 days at 4 C. The complex was broken down by heating, centrifuged, and the supernatant was used for inhibition. A 4.4-ng portion of the released antigen obtained from complex with HD antibody gave 50% inhibition compared with that of 3.8 ng obtained without antibody, therefore the recovery of HD antigen in supernatant was 86%. Table  II Detection o f HD antigen(s) in normal and pathologic sera: Before detection of HD antigen(s) in sera, an artificial immune-complex was made. The immunecomplex was dissociated by heating and the denatured antibody was separated from the glycoprotein (which is heat stable) by centrifugation. Figure 3 shows the inhibition curve of the recovered antigen as compared with the control containing no antibody. Taking the control as 100% recovery, the final recovery of the antigen after dissociation of the immune-complex was about 86% (from the amount of released antigen giving 50% inhibition). The supernatant was used for inhibition.
Five of the eight pathologic sera gave higher inhibition (4 and 5%) than 54 normal sera (1-3%) by the human system, while three pathologic sera gave higher inhibition of 4% than 53 of the normal sera by the chicken system. By the same procedure, 54 normal and eight cancer sera (whose antibody titers were examined as in Table II) were examined for presence of HD antigen(s). Table III shows that five (1, 2, 3, 4 and 8) of the eight cancer sera gave slightly higher inhibitions than the normal sera in the human system, while three (1, 3 and 4) had higher inhibition (4%) than 53 of the normal sera in the chicken system.
DISCUSSION
To test the applicability of this RIA system, the inhibitory potencies of cold glycoprotein and HD3 were compared in their reaction with both human and chicken HD antibodies.
In the case of human antibody, the glycoprotein was much more antigenic than HD3 (X50). Three possible reasons why HD3 gives a poor reaction may have been due to its micelle formation with taurodeoxycholate in aqueous medium, its fewer antigenic determinants, and a unique affinity of the antibody for the glycoprotein. However, the inhibitory potency of the glycopro-tein and that of HD3 were almost equal with respect to the chicken antibody.
This finding, therefore, excludes the first two possible reasons. It appears, therefore, that the human antibody has a unique affinity or specificity for the glycoprotein. Although both human and chicken antibodies are known to recognize the terminal sialic acid, the chicken antibody also recognizes some other part(s) of the respective molecule but the human antibody is very specific to Neu5Gc (9) . This quality of the chicken HD antibody may explain why it gave a poorer reaction with the antigens in cancer sera compared with the human antibody ( Table III) .
The chicken antibody may recognize a non-Neu5Gc portion of the antigen, thereby increasing the antigenic potency of the normal sera.
To explain the relationship between the expression of HD antigen in sera and elevation of HD antibodies in the respective sera, the respective RIAs were done. Compared with the normal sera, the cancer sera contained antigens reacted with both human and chicken antibodies and the cancer sera (except No. 2) giving higher inhibition (Nos. 1, 2, 3 and 8) had no detectable antibodies (Table II) . We predict that the immunological status of the sera was antigen excess at the time of obtaining them and a follow-up study of patients before and after therapy is indicated so as to explain the immunological status of such patients which may be of antigen antibody excess or immune-complex.
An artificial immune-complex of human HD antibody and the glycoprotein was made and later dissociated. Rather than determining the absolute contents of the inhibitor in sera, this experiment was intended to give the approximate proportion of the dissociated and separated antigen that was available for the inhibition study in cancer sera. 
